Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»274410.25742/NRIPH.2024.02.004Научная статьяOrganizational ways to increase the effectiveness of rehabilitation measures with botulinum toxinKizeevMihail V.m.kizeev@nriph.ruhttps://orcid.org/0000-0002-0293-8372BodunovAleksandr V.a.v.bodunov@gmail.comhttps://orcid.org/0009-0008-3367-6046NezhkinaNatal`ya N.natanezh@mail.comhttps://orcid.org/0000-0002-3731-130XNovikovAleksandr E.anovikov52@bmail.ruhttps://orcid.org/0000-0003-0561-1161GolubevaGalina A.golybevagalia@gmail.comhttps://orcid.org/0009-0007-3486-798XKulikovaYuliya A.kulikova_sr@mail.ruhttps://orcid.org/0009-0006-6356-6716N. A. Semashko National Research Institute of Public Health6Federal State Budgetary Healthcare Institution Reshma Medical Center of the Federal Medical Biological Agency of RussiaFederal State Budgetary Educational Institution of Higher Education «Ivanovo State Medical Academy» of the Ministry of Healthcare of the Russian Federation (FSBEI HE IvSMA MOH Russia)Federal State Budgetary Healthcare Institution Reshma Medical Center of the Federal Medical Biological Agency of Russia040620242252929042025Copyright © 2025,2025<p>One of the common movement disorders leading to limitation of life activity is spasticity. Medical rehabilitation plays a critical role in treating a patient's spasticity. The article presents an assessment of the organizational model of the sequence of rehabilitation measures using botulinum toxin type A using the example of the Federal State Budgetary Institution Reshma medical center of the FMBA of Russia. A comparative analysis of case histories of patients with spasticity in the arm who received injections of botulinum toxin type A in a 24-hour hospital with a profile of medical rehabilitation and a day hospital with a profile of neurology for 2022 and the first half of 2023 was carried out. It was determined that the organizational model of the sequence of rehabilitation activities using botulinum toxin type A at the Federal State Budgetary Institution Reshma medical center of the FMBA of Russia is a flexible system that can take into account the individual characteristics of each patient before his admission to the second stage of rehabilitation measures. Botulinum toxin injections can be used both before the second stage of rehabilitation and during the second stage of rehabilitation measures.</p>public healthorganizational structuremedical rehabilitationbotulinum toxinspasticityобщественное здоровьеорганизационная структурамедицинская реабилитацияботулинический токсинспастичность[Ivanova G.E., Mel`nikova E.V., Belkin A.A., Belyaev A.F., Bodrova R.A., Bujlova T.V., Mal`ceva M.N., MishinaI .E., Prokopenko S.V., Sarana A.M., Staxovskaya L.V., Xasanova D.R., Cykunov M.B., Shamalov N.A., Suvorov A.Yu., Shmonin A.A. How to organize medical rehabilitation? Bulletin of Rehabilitation Medicine. [Vestnik vosstanovitel`noj mediciny]. 2018;2(84):2—12 (in Russian).][Gimigliano F, NegriniS. The World Health Organization «Rehabilitation 2030: a call for action». Eur J Phys Rehabil Med. 2017;53(2):155—168. doi: 10.23736/S1973-9087.17.04746—3][Rivelis Y, Zafar N, MoriceK. Spasticity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 8, 2023.][Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, MozaffarT. A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Crit Rev Phys Rehabil Med. 2013;25(1—2):11—22. doi: 10.1615/CritRevPhysRehabilMed.2013007945][Bochkezanian V, Newton RU, Trajano GS, Blazevich AJ. Effects of Neuromuscular Electrical Stimulation in People with Spinal Cord Injury. Med Sci Sports Exerc. 2018;50(9):1733—1739. doi: 10.1249/MSS.0000000000001637][Emos MC, AgarwalS. Neuroanatomy, Upper Motor Neuron Lesion. In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 14, 2023.][Martino G, Ivanenko Y, Serrao M, et al. Locomotor coordination in patients with Hereditary Spastic Paraplegia. J Electromyogr Kinesiol. 2019;(45):61—69. doi: 10.1016/j.jelekin.2019.02.006][Marsden J, Stevenson V, JarrettL. Treatment of spasticity. Handb Clin Neurol. 2023;(196):497—521. doi: 10.1016/B978-0-323-98817-9.00010—7][Khasanova D.R., Agafonova N.V., Starostina G.Kh., Krylova L.V. Post-stroke spasticity. Consilium Medicum. [Consilium Medicum]. 2016;18(2):31—36 (in Russian).][10.Wissel J, Ri S, KiviA. Early versus late injections of Botulinumtoxin type A in post-stroke spastic movement disorder: A literature review. Toxicon. 2023;(229):107150. doi: 10.1016/j.toxicon.2023.107150][Santamato A. Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity. Neuropsychiatr Dis Treat. 2016;(12):251—263. doi: 10.2147/NDT.S86978][Elovic EP, Munin MC, Kaňovský P, Hanschmann A, Hiersemenzel R, MarciniakC. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity [published correction appears in Muscle Nerve. 2016 Jun;54(1):170]. Muscle Nerve. 2016;53(3):415—421. doi: 10.1002/mus.24776][Antipenko E.A., Gustov A.V. Possibilities and prospects for the use of botulinum toxin in neurological practice. Modern Technologies in Medicine. [Sovremennye tehnologii v medicine]. 2011;(1):102—104 (in Russian).][Ghroubi S, Alila S, Elleuch W, Ayed HB, Mhiri C, Elleuch MH. Efficacy of botulinum toxin A for the treatment of hemiparesis in adults with chronic upper limb spasticity. Pan Afr MedJ. 2020;(35):55. doi:10.11604/pamj.2020.35.55.16091]